BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16840725)

  • 21. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha.
    Ohashi A; Kinoshita K; Isozaki K; Nishida T; Shinomura Y; Kitamura Y; Hirota S
    Int J Cancer; 2004 Sep; 111(3):317-21. PubMed ID: 15221957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
    Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
    Kindler T; Breitenbuecher F; Marx A; Beck J; Hess G; Weinkauf B; Duyster J; Peschel C; Kirkpatrick CJ; Theobald M; Gschaidmeier H; Huber C; Fischer T
    Blood; 2004 May; 103(10):3644-54. PubMed ID: 14726395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
    Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
    Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
    Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
    Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
    Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid rafts are required for Kit survival and proliferation signals.
    Jahn T; Leifheit E; Gooch S; Sindhu S; Weinberg K
    Blood; 2007 Sep; 110(6):1739-47. PubMed ID: 17554062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
    Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
    Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
    Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; RaschellĂ  G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.